Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T

Inclusion Criteria: * Cancer of prostate * Evidence of metastasis * Failed available therapies * Resolution of any toxic effects of previous therapies * Performance status (ECOG PS) 0-2 * Adequate hematologic, coagulation (INR 2-3max), hepatic and renal function * Life expectancy of 12 months * Agrees to contraceptive use while on study if sexually active * Sign informed consent document Exclusion Criteria: * Any condition presenting an unacceptably high anesthetic or surgical risk * HIV positive * Cognitive impairment such as to preclude informed consent * Other surgical treatment, chemotherapy and radiation within four weeks of baseline * Inadequate hematologic, coagulation (INR \>3), hepatic, renal function * Hepatic blood flow abnormalities and/or large-volume ascites * Concurrent cancer of any other type except skin cancer (excluding melanoma) * History of allergic reactions to mouse antigens * Active infection, congestive heart failure, unstable angina, serious cardiac arrhythmias, psychiatric illness, difficult social situations not permitting reliable participation, active bleeding